Abstract
Clozapine is an atypical antipsychotic agent with immunomodulatory properties. We hypothesized that in vitro immune parameters of peripheral blood mononuclear cells (PBMC) are affected in the course of clozapine treatment and that clozapine per se, added in vitro to PBMC cultures of clozapine-treated patients, exerts differential effects in the timecourse of treatment in vivo. We measured proliferation and cytokine secretion of PBMC, serum autoantibodies, and immunoglobulin levels in 17 patients before and during the first 6 weeks of clozapine treatment. Independent of clozapine dosage and rectal temperature, clozapine treatment in vivo suppressed proliferation and shedding of sIL-2r by PBMC, and the addition of clozapine in vitro induced, relative to unstimulated conditions, PBMC proliferation and secretion of IL-6 and sIL-2r. Serum IgG levels were increased; whereas, autoantibody pattern was unaffected. Thus, clozapine treatment and the addition of clozapine in vitro exert differential effects on various in vitro immune parameters independent of clozapine dosage and rectal temperature in the course of treatment.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Ackenheil M . (1989): Clozapine—Pharmacokinetic investigations and biochemical effects in man. Psychopharmacology 99: S32–S37
American Psychiatric Association. (1987): Diagnostic and Statistical Manual of Mental Disorders, 3rd ed rev. Washington, DC, American Psychiatric Press
Baldessarini RJ, Frankenburg FR . (1991): Clozapine, a novel antipsychotic agent. N Engl J Med 324: 746–754
Berg PA, Becker EW . (1995): The lymphocyte transformation test—A debated method for the evaluation of drug allergic hepatic injury. J Hepatol 22: 115–118
Blum A, Mauruschat W . (1972): Temperaturanstiege und Bluteiweißveränderungen unter der Therapie mit Neuroleptika—unter besonderer Berücksichtigung des neuartigen Dibenzodiazepinderivates Clozapin. Pharmakopsychiatr 5: 155–169
Canoso RT, de Oliviera RM, Nixon RA . (1990): Neuroleptic-associated autoantibodies—A prevalence study. Biol Psychiatry 27: 863–870
Chengappa KN, Carpenter AB, Yang ZW, Brar JS, Rabin BS, Ganguli R . (1992): Elevated IgG antihistone antibodies in a subgroup of medicated schizophrenic patients. Schizophr Res 7: 49–54
Chengappa KN, Ganguli R, Yang ZW, Shurin G, Brar JS, Rabin BS . (1995): Impaired mitogen (PHA) responsiveness and increased autoantibodies in Caucasian schizophrenic patients with the HLA B8/DR3 phenotype. Biol Psychiatry 37: 546–549
Davis S, Kern HB, Asokan R . (1994): Antiphospholipid antibodies associated with clozapine treatment. Am J Hematol 46: 166–167
Engvall E . (1980): Enzyme immunoassay ELISA and EMIT. Methods Enzymol 70: 419–439
Ganguli R, Rabin BS, Brar JS . (1992): Antinuclear and gastric parietal cell autoantibodies in schizophrenic patients. Biol Psychiatry 32: 735–738
Hasegawa M, Cola PA, Meltzer HY . (1994): Plasma clozapine and desmethylclozapine levels in clozapine-induced agranulocytosis. Neuropsychopharmacology 11: 45–47
Hasegawa M, Gutierrez-Esteinou R, Way L, Meltzer HY . (1993): Relationship between clinical efficacy and clozapine plasma levels in schizophrenia: Effect of smoking. J Clin Psychopharmacol 13: 383–390
Henneberg AE, Horter S, Ruffert S . (1994): Increased prevalence of antibrain antibodies in the sera from schizophrenic patients. Schizo Res 14: 15–22
Hinze-Selch D, Becker EW, Stein G, Schreiber W, Pollmächer T . (1996): Clozapine-induced parotitis: An immunological cause? Am J Psychiatry 153: 840
Klein R, Berg PA . (1994): A comparative study on antibodies to nucleoli and 5-hydroxytryptamine in patients with fibromyalgia syndrome and tryptophan-induced eosinophilia myalgia syndrome. Clin Invest 72: 541–549
Lai JCK, Clark JB . (1979): Preparation of synaptic and non-synaptic mitochondria from mammalian brain. Methods Enzymol 55: 51–60
Levy-Soussan P, Barbouche R, Poirier MF, Galinowski A, Loo H, Avrameas S . (1994): A preliminary prospective study on natural autoantibodies and the response of untreated schizophrenic patients to neuroleptics. Biol Psychiatry 35: 135–138
Lloyd AR, Oppenheim JJ . (1992): Poly's lament: The neglected role of the polymorphonuclear neutrophil in the afferent limb of the immune response. Immunol Today 13: 169–172
Maes M, Bosmans E, Calabrese J, Smith R, Meltzer HY . (1995): Interleukin-2 and interleukin-6 in schizophrenia and mania: Effects of neuroleptics and mood stabilizers. J Psychiat Res 29: 141–152
Maes M, Meltzer HY, Bosmans E . (1994): Immune-inflammatory markers in schizophrenia: Comparison to normal controls and effects of clozapine. Acta Psychiatr Scand 89: 346–351
McAllister CG, Rapaport MH, Pickar D, Paul SM . (1989): Effects of short-term administration of antipsychotic drugs on lymphocyte subsets in schizophrenic patients. Arch Gen Psychiatry 46: 956–957
Pisciotta AV, Konings SA . (1994): 51Cr release assay of clozapine-induced cytotoxicity: Evidence for immunogenic mechanism. J Clin Psychiatry 55: 143–148
Pollmächer T, Fenzel T, Mullington J, Hinze-Selch D . (1997a): The influence of clozapine treatment on plasma granulocyte colony-stimulating factor (G-CSF) levels. Pharmacopsychiatry 30: 118–121
Pollmächer T, Hinze-Selch D, Fenzel T, Kraus T, Schuld A, Mullington J . (1997b): Plasma levels of cytokines and soluble cytokine receptors during treatment with haloperidol. Am J Psychiatry 154: 1763–1765
Pollmächer T, Hinze-Selch D, Mullington J . (1996): Effects of clozapine on cytokines and soluble cytokine receptors. J Clin Psychopharmacol 16: 403–409
Pollmächer T, Hinze-Selch D, Mullington J, Holsboer F . (1995): Clozapine-induced increase in plasma levels of soluble interleukin-2 receptors. Arch Gen Psychiatry 52: 877–878
Rapaport H, McAllister CG, Kirch DG, Pickar D . (1990): The effect of typical and atypical neuroleptics on mitogen-induced T lymphocyte responsiveness. Biol Psychiatry 29: 715–717
Sperner-Unterweger B, Gaggl S, Fleischhacker WW, Barnas C, Herold M, Geissler D . (1993): Effects of clozapine on hematopoiesis and the cytokine system. Biol Psychiatry 34: 536–543
Stevens A, Weller M . (1992): Ganglioside antibodies in schizophrenia and major depression. Biol Psychiatry 32: 727–730
Uetrecht JP . (1992): Metabolism of clozapine by neutrophils—Possible implications for clozapine-induced agranulocytosis. Drug Safety 7: 51–56
Acknowledgements
The authors thank Alexander Yassouridis, Ph.D. for his excellent and expert statistical assistance.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hinze-Selch, D., Becker, E., Stein, G. et al. Effects of Clozapine on In Vitro Immune Parameters: A Longitudinal Study in Clozapine-Treated Schizophrenic Patients. Neuropsychopharmacol 19, 114–122 (1998). https://doi.org/10.1016/S0893-133X(98)00006-2
Received:
Revised:
Accepted:
Issue date:
DOI: https://doi.org/10.1016/S0893-133X(98)00006-2
Keywords
This article is cited by
-
Pro-inflammatory cytokine levels are elevated in female patients with schizophrenia treated with clozapine
Psychopharmacology (2022)
-
Localisation of clozapine during experimental autoimmune encephalomyelitis and its impact on dopamine and its receptors
Scientific Reports (2021)
-
The Potential Use of Peripheral Blood Mononuclear Cells as Biomarkers for Treatment Response and Outcome Prediction in Psychiatry: A Systematic Review
Molecular Diagnosis & Therapy (2021)
-
The role of sulpiride in attenuating the cardiac, renal, and immune disruptions in rats receiving clozapine: mRNA expression pattern of the genes encoding Kim-1, TIMP-1, and CYP isoforms
Environmental Science and Pollution Research (2020)
-
Effects of psychotropic drugs on inflammation: consequence or mediator of therapeutic effects in psychiatric treatment?
Psychopharmacology (2016)
